Difference between revisions of "Team:NTU SINGAPORE/Basic Part"
Kasturi001 (Talk | contribs) |
|||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 13: | Line 13: | ||
| − | |||
| Line 21: | Line 20: | ||
<pstyle="text-align:center"> Functional units of DNA.</p> | <pstyle="text-align:center"> Functional units of DNA.</p> | ||
</div> | </div> | ||
| − | |||
<div id='groupparts' style='min-height:100px;width:1084px;margin:auto;'><div style='width:300px;margin:auto;padding:20px;color:gray;border:1px solid gray'>Loading…..</div></div><script>$('#groupparts').load('/cgi/api/groupparts.cgi', { t:'iGEM2017', g:'NTU_Singapore' },function(){ $('#groupparts .tablesorter').tablesorter();} );</script> | <div id='groupparts' style='min-height:100px;width:1084px;margin:auto;'><div style='width:300px;margin:auto;padding:20px;color:gray;border:1px solid gray'>Loading…..</div></div><script>$('#groupparts').load('/cgi/api/groupparts.cgi', { t:'iGEM2017', g:'NTU_Singapore' },function(){ $('#groupparts .tablesorter').tablesorter();} );</script> | ||
| + | |||
<div class="column full_width"> | <div class="column full_width"> | ||
| Line 32: | Line 31: | ||
| − | <div class=" | + | <div class="ex column full_width"> |
| − | + | ||
<p>dCas9 is a catalytically inactive Cas9, which still retains it's ability to bind to DNA. For epigenetic regulation, the dCas9 is highly dependent upon the function of it's fusion partner.</p> | <p>dCas9 is a catalytically inactive Cas9, which still retains it's ability to bind to DNA. For epigenetic regulation, the dCas9 is highly dependent upon the function of it's fusion partner.</p> | ||
| − | |||
<p>For this part, we have deleted the HNH domain, Rec2 domain and RuvCIII-2 domain of the SP-dCas9. The triple truncation (∆REC2 ∆RuvCIII-2 ∆HNH, referred to as ‘∆3ple’) is especially of interest since it reduces the size of the dCas9 gene to around 3.2kB which is on par with the size of Sa-Cas9. The ∆3ple truncation has slightly lower activation compared to double truncation. In order to improve the activity of ∆3ple dCas9, quick changes are further performed at the various site of dCas9. Combination of quick change at Asn497Lys (QC5), Thr657Lys (QC6) and Ser1109Arg (QC15) show improved activity. Its binding capability was tested by assessing the strength in transcriptional activation via by tagging it with a VP64-p65-Rta tripartite activator.</p> | <p>For this part, we have deleted the HNH domain, Rec2 domain and RuvCIII-2 domain of the SP-dCas9. The triple truncation (∆REC2 ∆RuvCIII-2 ∆HNH, referred to as ‘∆3ple’) is especially of interest since it reduces the size of the dCas9 gene to around 3.2kB which is on par with the size of Sa-Cas9. The ∆3ple truncation has slightly lower activation compared to double truncation. In order to improve the activity of ∆3ple dCas9, quick changes are further performed at the various site of dCas9. Combination of quick change at Asn497Lys (QC5), Thr657Lys (QC6) and Ser1109Arg (QC15) show improved activity. Its binding capability was tested by assessing the strength in transcriptional activation via by tagging it with a VP64-p65-Rta tripartite activator.</p> | ||
</div> | </div> | ||
| − | + | ||
| − | + | ||
</br> | </br> | ||
Latest revision as of 02:55, 2 November 2017
Basic Part
∆RuvCIII-2 ∆HNH ∆REC2 Sp-dCas9 Enhanced
dCas9 is a catalytically inactive Cas9, which still retains it's ability to bind to DNA. For epigenetic regulation, the dCas9 is highly dependent upon the function of it's fusion partner.
For this part, we have deleted the HNH domain, Rec2 domain and RuvCIII-2 domain of the SP-dCas9. The triple truncation (∆REC2 ∆RuvCIII-2 ∆HNH, referred to as ‘∆3ple’) is especially of interest since it reduces the size of the dCas9 gene to around 3.2kB which is on par with the size of Sa-Cas9. The ∆3ple truncation has slightly lower activation compared to double truncation. In order to improve the activity of ∆3ple dCas9, quick changes are further performed at the various site of dCas9. Combination of quick change at Asn497Lys (QC5), Thr657Lys (QC6) and Ser1109Arg (QC15) show improved activity. Its binding capability was tested by assessing the strength in transcriptional activation via by tagging it with a VP64-p65-Rta tripartite activator.
